-

Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting

LONDON & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces it will present a poster entitled ‘AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-a) mediated cleavage’, at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place at Orange County Convention Center, Orlando, Florida on 16 April.

The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company’s second pre|CISION™ candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor. AVA3996 utilises Avacta’s pre|CISION™ platform to improve the therapeutic index and therefore utility of proteasome inhibitors in tumours with high FAP levels, including both solid and haematological tumours. AVA3996 has the potential to deliver efficacious levels of the proteasome inhibitor warhead directly to the tumour microenvironment while reducing systemic exposure and hence associated toxicities, such as peripheral neuropathy.

Attending the conference from Avacta will be Fiona McLaughlin – Chief Scientific Officer, Neil Bell – Chief Development Officer, David Jones – VP Biology and Francis Wilson – VP Chemistry.

Poster Presentation Title

AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via fibroblast activation protein-alpha (FAP-a) mediated cleavage

Session Category

Experimental and Molecular Therapeutics

Session Title

Targeting the Tumour Microenvironment

Session Date and Time

April 16, 2023 1:30 PM – 5:30 PM ET

Location

Orange County Convention Center, Section 20

Poster Board Number

17

Abstract Presentation Number

583

The abstract is available via the AACR annual meeting website, here: https://www.abstractsonline.com/pp8/#!/10828/presentation/2606

Copies of the poster will be available on Avacta’s website following the conference at: https://avacta.com/about/resources/posters/

Alastair Smith, Avacta Chief Executive Officer, will provide a video presentation overview for investors examining the data presented in the poster. This will be available on 17th April at https://avacta.com/investors/documents-presentations/

Contacts

Lily Jeffery, Zyme Communications
T: +44 (0)7891 477 378
E: lily.jeffery@zymecommunications.com

Avacta Group plc


Release Versions

Contacts

Lily Jeffery, Zyme Communications
T: +44 (0)7891 477 378
E: lily.jeffery@zymecommunications.com

More News From Avacta Group plc

Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study

LONDON & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully. The data continue to show a very favourable safety profile for the tumour targeted chemotherapy and several patients in cohort 5 a...

First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study

LONDON & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational New Drug (IND) Application in Avacta’s phase 1 multi-centre trial evaluating the safety and tolerability of AVA6000, a novel tumour targeted form of doxorubicin and Avacta’s first therapeutic product based on its proprietary pre|CISION™ techno...

Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study

LONDON & WETHERBY, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening on 5 April 2023 of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug (IND) Application.The two sites, Memorial Sloan Kettering Cancer Center (MSK) in New York and Fred Hutch Cancer Center in Seattle, are now open for patient enrolmen...
Back to Newsroom